Drugs / HXN6005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07449741 | Apr 2026 → Mar 2027 expected | — | Helixon Biotechnology (Suzhou) Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HXN6005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07449741 ↗ |
| Route | Subcutaneous | “participants will receive a single subcutaneous dose of HXN6005 at escalating dose levels in Cohort 1-4,” NCT07449741 ↗ |